Richmond Research Institute is proud to take part in Heart Failure 2025, the annual congress of the Heart Failure Association of the ESC, to be held this year in Serbia. This flagship event provides a vital forum for advancing clinical practice, scientific innovation, and global collaboration in the field of heart failure and related cardiovascular diseases.
Gathering leading experts from around the world, the congress will showcase cutting-edge developments in cardiology, digital health, and novel strategies for managing heart failure.
Attending on behalf of Richmond Research Institute:
James Rickard will present two research posters and will be available throughout the event to discuss Richmond Research Institute’s role in cardiovascular drug development. His presentations will cover:
If you’ll be attending HFA 2025 and are looking for an experienced partner in cardiovascular research, we welcome the opportunity to connect.
For meeting requests or collaboration enquiries:
📧 info@richmondresearchinstitute.com
Learn more about the event: Heart Failure 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and...
Authored by Georg Ferber, PhD, Dilshat Djumanov, PhD, Ulrike Lorch, MD, FFPM, Edward Jackson, BSc, MSc, PhD, MBChB, Joao Almeida Melo, James Rickard, MPharm, and Jorg Taubel, MD, FFPM, FESC.
RRI Lead Specialty Research Physician wins award for Cardiovascular risk factor analysis of data associated with UK grocery brand Tescos
We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.
Here we present the results of our recent work on the cardiac safety of cortexolone 17α-propionate (cortexolone).
12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.
Dr. Taubel explains to the New Scientist why patient safety is pivotal in phase I trials
Here we report our recent work on the cardiac safety of nolasiban.
Findings from our recent study show how cardiac ion channel blocking agents could increase the risk of sudden cardiac death in patients with type 1 diabetes, particularly in women.